Phase Ⅰ clinical trial design and the problems need to focus

Abstract

CLC Number:

R969

QIAN Wei, XIAO Da-wei. Phase Ⅰ clinical trial design and the problems need to focus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 654-660.

[1] Buoen C, Bjerrum OJ, Thomsen MS. How first-time-in-human studies are being performed:a survey of phase Ⅰ dose-escalation trials in healthy volunteers published between 1995 and 2004[J].Clin Pharmacol,2005,45(10):1123-1126.
[2] ABPI. Guidelines for Phase Ⅰ Clinical Trials[EB/OL].http://www.abpi.org.uk/our-work/ library/guidelines/Pages/phase-1-trials.aspx
[3] Tanguay M.Phase i efficiency[EB/OL].http://www.samedanltd.com/magazine/13/issue/130 /article/2662
[4] Eypasch E, Lefering R, Kum C, et al. Probability of adverse events that have not yet occurred:a statistical[J].BMJ,1995,(311):619-620.
[5] FDA,Center for Drug Evaluation and Research (CDER).Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers[EB/OL].http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065014.htm.
[6] Expert scientific group on phase one clinical trials(ESG).Final report of the Expert Scientific Group [EB/OL].http://www.trialformsupport.com/business/doc/Final_Report_of_ the_Expert_Scientific_Group_(ESG).pdf
[7] EMEA,Cmmittee for Medicinal Products for Human Use(CHMP).Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products[EB/OL].http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf
[8] ABPI/BIA.Early stage clinical trial taskforce[EB/OL].http://www.abpi.org.uk/information /pdfs/BIAABPI_taskforce2.pdf
[9] Lowe PJ, Hijazi Y, Luttringer O, et al. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development[J]. Xenobiotica, 2007,37(10/11):1331-1354.
[10]Mahmood I,Balian J.Interspecies scaling:Predicting clearance of drugs in humans.Three different approaches[J].Xenobiotica,1996,26(9):887-895.
[11]Mahmood I,Balian J.The pharmacokinetic principles behind scaling from preclinical results to phase I protocols[J].J Clin Pharmacol,1999,36(1):1-11.
[12]Obach R,Baxter J,Liston T, et al.The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data[J]. J Pharmacol Exp Ther, 1997,283(1):46-58.
[13]Ito K, Houston J. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches[J].Pharmacol Res,2005,22(1):103-112.
[14]Jones HM, Parrott N, Jorga K,et al.A novel strategy for physiologically based predictions of human pharmacokinetics[J].Clin Pharmacokinetics,2006,45(5):511-542.
[15]Hosea N, Collard W, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches[J].J Clin Pharmacol,2009,49(5):513-533.
[16]Williams P,O'Connell D,Dewit O.First in human studies: points to consider in study placement, design and conduct[EB/OL].http://www.abpi.org.uk/our-work/library/guidelines/ Documents/First%20in%20Human%20Studies.pdf
[17]Sellers E,Souich P,Chapter 6.Phase Ⅰ studies (human pharmacology)[EB/OL].http://ww w.iuphar.org/pdf/hum_40.pdf
[18]汪秀琴,熊宁宁,刘芳,等.临床试验的风险评估与安全监察[J].中国新药,2005,14:520-523.
[19]MRC/DH joint project,Trial management and monitoring A) clinical trial risk assessment[EB/OL].http://www.ct-toolkit.ac.uk/_db/_documents/Trial_RA.pdf
[20]MRC/DH joint project,Trial management and monitoring A) clinical trial risk assessment[EB/OL].http://www.ct-toolkit.ac.uk/_db/_documents/Trial_RA.pdf

Phase Ⅰ clinical trial design and the problems need to focus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LU Kepeng, LIU Caihong, BI Ying. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1269-1274.
[2]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[3]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[4]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[5]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[6]	JIANG Daoli, CHOU Xiaohua, LIU Zhidong, LI Wei, ZHANG Bo, XU Sang, TAN Defei, FANG Yi, LV Dongmei, WANG Tao. Real-world study of ceftazidime-avibactam in the treatment of multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1008-1017.
[7]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[8]	WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048.
[9]	HUA Zhihui, LIU Dong, ZHANG Jiandong, CAI Siyu, GE Chunli, CHEN Nan, QI Qi. Clinical evaluation of the efficacy against helicobacter pylori by amoxicillin from volume-based procurement and potassium amoxicillin clavulanate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1061-1066.
[10]	ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
[11]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai. Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766.
[12]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[13]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[14]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[15]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.